Alexander Goldfarb
About Alexander Goldfarb
Alexander Goldfarb is a Senior Medical Director at Inozyme Pharma and a Lecturer at Harvard Medical School. He has extensive experience in nephrology and biomedical informatics, having held various academic and medical positions across several institutions.
Current Role at Inozyme Pharma
Alexander Goldfarb serves as the Senior Medical Director at Inozyme Pharma, a position he has held since 2020. In this role, he contributes to the development and implementation of medical strategies that align with the company's mission in the biotechnology sector. His expertise in nephrology and critical care medicine supports the company's focus on innovative therapies.
Academic Involvement at Harvard Medical School
Goldfarb has been a Lecturer at Harvard Medical School since 2007. His role involves educating medical students and professionals, sharing his extensive knowledge in nephrology and biomedical informatics. His academic contributions enhance the learning experience for students pursuing careers in medicine.
Previous Experience in Academia and Medicine
Prior to his current roles, Goldfarb worked as an Assistant Professor of Medicine at the University of Utah School of Medicine from 2001 to 2007. He also completed a Nephrology Fellowship at Stanford University from 1999 to 2001. His experience includes a Medical Residency at The New York Hospital Medical Center of Queens from 1996 to 1999.
Educational Background in Medicine and Mathematics
Goldfarb's educational journey includes a Medical Doctorate from Izhevsk State Medical Academy, completed in 1986, and a Master of Science in Mathematics from Udmurt State University, achieved in 1988. He further advanced his medical training with a Ph.D. in Biomedical Informatics from the University of Utah, completed in 2007, and a Critical Care Medicine training at Tel Aviv University.
Professional Experience in Medical Directorship
Goldfarb held the position of Medical Director at Akebia Therapeutics from 2018 to 2020. His responsibilities included overseeing clinical development and medical affairs, contributing to the company's strategic objectives in the field of nephrology. This role built upon his extensive background in both clinical and academic medicine.